These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24353908)

  • 1. New prospects on the NKG2D/NKG2DL system for oncology.
    Ullrich E; Koch J; Cerwenka A; Steinle A
    Oncoimmunology; 2013 Oct; 2(10):e26097. PubMed ID: 24353908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NKG2D axis: an emerging target in cancer immunotherapy.
    Lazarova M; Steinle A
    Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
    Kim Y; Born C; Bléry M; Steinle A
    Front Immunol; 2020; 11():960. PubMed ID: 32582150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
    Lazarova M; Wels WS; Steinle A
    Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of NKG2D/NKG2D ligand interaction attenuated cardiac remodelling after myocardial infarction.
    Matsumoto K; Obana M; Kobayashi A; Kihara M; Shioi G; Miyagawa S; Maeda M; Sakata Y; Nakayama H; Sawa Y; Fujio Y
    Cardiovasc Res; 2019 Mar; 115(4):765-775. PubMed ID: 30307485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
    Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
    Front Immunol; 2018; 9():620. PubMed ID: 29651291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.
    Paschen A; Baingo J; Schadendorf D
    Eur J Cell Biol; 2014; 93(1-2):49-54. PubMed ID: 24629838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
    Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
    J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study.
    de Kruijf EM; Sajet A; van Nes JG; Putter H; Smit VT; Eagle RA; Jafferji I; Trowsdale J; Liefers GJ; van de Velde CJ; Kuppen PJ
    BMC Cancer; 2012 Jan; 12():24. PubMed ID: 22257486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
    Lazarova M; Steinle A
    Front Immunol; 2019; 10():2689. PubMed ID: 31803194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative genomics of the NKG2D ligand gene family.
    Kasahara M; Sutoh Y
    Immunol Rev; 2015 Sep; 267(1):72-87. PubMed ID: 26284472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors.
    Chitadze G; Lettau M; Luecke S; Wang T; Janssen O; Fürst D; Mytilineos J; Wesch D; Oberg HH; Held-Feindt J; Kabelitz D
    Oncoimmunology; 2016 Apr; 5(4):e1093276. PubMed ID: 27141377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.